IP Library Granted Patent US 8,815,535
Granted Patent B2
US 8,815,535 · App. 13/559,060 · Granted Aug 26, 2014

Disk diffusion assay for oritavancin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,815,535
App. No.
13/559,060
Granted
Aug 26, 2014
Kind
B2
Abstract

The present invention is directed to a disk diffusion assay for determining susceptibility of bacteria to a glycopeptide antibiotic. The assay includes improvements over conventional assays due to the inclusion of polysorbate 80 and Span 80 in the antibacterial solution used to impregnate paper disks used in the assay.

Claims (28)

1. A disk diffusion assay for determining susceptibility of bacteria to oritavancin, said assay comprising:

a) impregnating a paper disk with a solution comprising oritavancin, polysorbate 80 and sorbitane monooleate (Span 80),

b) placing the impregnated disk on the surface of a bacteria-coated media plate,

c) incubating the plate of b) under conditions promoting bacterial growth, and

d) measuring a zone of inhibition around the disk.

2. The disk diffusion assay of claim 1 , wherein the disk is impregnated with about 25 μg of oritavancin.

3. The disk diffusion assay of claim 2 , wherein polysorbate 80 and Span 80 are present in the solution at a ratio of from about 60:40 to about 40:60 v/v and wherein polysorbate 80 and Span 80 are present in the solution at a combined concentration of between about 2.5% and about 5.5% v/v.

4. The disk diffusion assay of claim 2 , wherein polysorbate 80 and Span 80 are present in the solution at a ratio of about 50:50 v/v and wherein polysorbate 80 and Span 80 are present in the solution at a combined concentration of about 4% v/v.

5. The disk diffusion assay of claim 2 , wherein the impregnated disk is dried at room temperature before it is placed on the bacteria-coated media plate.

6. The disk diffusion assay of claim 2 , wherein the incubating step c) is conducted at about 37° C.

7. The disk diffusion assay of claim 2 , wherein the zone of inhibition measured in d) is at least about 15 mm in diameter.

8. The disk diffusion assay of claim 1 , wherein polysorbate 80 and Span 80 are present in the solution at a ratio of from about 60:40 to about 40:60 v/v and wherein polysorbate 80 and Span 80 are present in the solution at a combined concentration of between about 2.5% and about 5.5% v/v.

9. The disk diffusion assay of claim 1 , wherein polysorbate 80 and Span 80 are present in the solution at a ratio of about 50:50 v/v and wherein polysorbate 80 and Span 80 are present in the solution at a combined concentration of about 4% v/v.

10. The disk diffusion assay of claim 1 , wherein the impregnated disk is dried at room temperature before it is placed on the bacteria-coated media plate.

11. The disk diffusion assay of claim 1 , wherein the incubating step c) is conducted at about 37° C.

12. The disk diffusion assay of claim 1 , wherein the zone of inhibition measured in d) is at least about 15 mm in diameter.

13. A disk diffusion assay for determining susceptibility of bacteria to oritavancin, said assay comprising:

a) impregnating a paper disk with a solution comprising oritavancin, polysorbate 80 and Span 80, wherein the oritavancin is present at a concentration of about 1.25 mg/ml, and wherein the polysorbate 80 and Span 80 are present in the solution at a combined concentration of about 4% v/v and in a ratio of about 50:50 v/v,

b) placing the impregnated disk on the surface of a bacteria-coated media plate,

c) incubating the plate of b) under conditions promoting bacterial growth, and

d) measuring a zone of inhibition around the disk.

14. The disk diffusion assay of claim 13 , wherein the disk is impregnated with about 25 μg of oritavancin.

15. The disk diffusion assay of claim 14 , wherein the impregnated disk is dried at room temperature before it is placed on the bacteria-coated media plate.

16. The disk diffusion assay of claim 14 , wherein the incubating step c) is conducted at about 37° C.

17. The disk diffusion assay of claim 14 , wherein the zone of inhibition measured in d) is at least about 15 mm in diameter.

18. The disk diffusion assay of claim 13 , wherein the impregnated disk is dried at room temperature before it is placed on the bacteria-coated media plate.

19. The disk diffusion assay of claim 13 , wherein the incubating step c) is conducted at about 37° C.

20. The disk diffusion assay of claim 13 , wherein the zone of inhibition measured in d) is at least about 15 mm in diameter.

Assignments (5)
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (PATENTS) AT REEL 054836 AND FRAME 0765 AND REEL 061314 AND 0459 Recorded Aug 29, 2025
From: SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY
To: MELINTA THERAPEUTICS, LLC
Reel/Frame 072772/0097 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2022
From: MELINTA THERAPEUTICS, LLC
To: SILICON VALLEY BANK
Reel/Frame 061314/0459 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2019
From: THE MEDICINES COMPANY
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 048407/0911 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2012
From: BELLEY, ADAM
To: THE MEDICINES COMPANY
Reel/Frame 028828/0227 →